Additional file 9: of Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

Assessment of time-course changes in %DLCO in Drug-treated patients with borderline or less severe PH. A summary of results for %DLCO. (PPTX 117 kb)